Drug · CHEMBL787
MONTELUKAST
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. MONTELUKAST. Drugs and targets, record CHEMBL787. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL787
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 4 of its 55 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CYSLTR1 | Cysteinyl leukotriene receptor 1 | Cysteinyl leukotriene receptor 1 antagonist | ANTAGONIST | https://conductscience.org/library/genes/10800 |
Source ChEMBL
Diseases55
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 55Source Open Targets
See all 55 diseasesTrials278
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04885530 | ACTIV-6: COVID-19 Study of Repurposed Medications | Phase 3 | 10,956 | 2025-11-17 | montelukast | Its name | ClinicalTrials.gov |
| NCT00092118 | The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265) | Phase 3 | 1,992 | 2010-07-23 | montelukast | Its name | ClinicalTrials.gov |
| NCT00979901 | Montelukast in Patients With Seasonal Allergic Rhinitis - Spring 2000 Study (MK-0476A-162)(COMPLETED) | Phase 3 | 1,577 | 2010-06-08 | montelukast | Its name | ClinicalTrials.gov |
| NCT05894577 | ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast) | Phase 3 | 1,453 | 2024-08-16 | montelukast | Its name | ClinicalTrials.gov |
| NCT00974571 | Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246) | Phase 3 | 1,365 | 2010-06-07 | montelukast | Its name | ClinicalTrials.gov |
| NCT00972738 | Montelukast in Seasonal Allergic Rhinitis - Spring 2001 Study (0476-235) | Phase 3 | 1,214 | 2010-06-16 | montelukast | Its name | ClinicalTrials.gov |
| NCT00461032 | Montelukast Back to School Asthma Study (0476-340) | Phase 3 | 1,162 | 2010-02-04 | montelukast | Its name | ClinicalTrials.gov |
| NCT00963469 | Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240) | Phase 3 | 1,079 | 2010-06-09 | montelukast | Its name | ClinicalTrials.gov |
| NCT00963599 | Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117) | Phase 3 | 907 | 2010-06-16 | montelukast | Its name | ClinicalTrials.gov |
| NCT00960141 | A Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic Rhinitis (MK-0476-192)(COMPLETED) | Phase 3 | 829 | 2010-06-09 | montelukast | Its name | ClinicalTrials.gov |
1 to 10 of 278
See all 278 trialsComparisons in its trials57
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Montelukast vs Fluticasone: deaths from any cause | 0 of 12,569 | 0 of 12,569 | 25,138 | NCT05457855 | Trial comparisons |
| Montelukast 10 mg vs Placebo: serious adverse events | 4 of 1,002 | 1 of 990 | 1,992 | NCT00092118 | Trial comparisons |
| Arm F - Montelukast vs Arm F - Placebo: Number of Participants With Mortality | 0 of 628 | 0 of 622 | 1,250 | NCT05894577 | Trial comparisons |
| Arm F - Montelukast vs Arm F - Placebo: Number of Participants With Hospitalization or Death | 2 of 628 | 2 of 622 | 1,250 | NCT05894577 | Trial comparisons |
| Arm F - Montelukast vs Arm F - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death | 18 of 628 | 18 of 622 | 1,250 | NCT05894577 | Trial comparisons |
| Arm F - Montelukast vs Arm F - Placebo: deaths from any cause | 0 of 628 | 0 of 622 | 1,250 | NCT05894577 | Trial comparisons |
| Arm F - Montelukast vs Arm F - Placebo: serious adverse events | 6 of 628 | 3 of 622 | 1,250 | NCT05894577 | Trial comparisons |
| Montelukast 5 mg vs Placebo: serious adverse events | 4 of 566 | 1 of 566 | 1,132 | NCT00461032 | Trial comparisons |
| FF 50 mcg vs Placebo: Number of Participants With On-treatment Asthma Exacerbations Over Double-blind Treatment Period | 7 of 238 | 22 of 239 | 477 | NCT02889809 | Trial comparisons |
| FF 50 mcg vs Placebo: deaths from any cause | 0 of 238 | 0 of 239 | 477 | NCT02889809 | Trial comparisons |
1 to 10 of 57
See all 57 comparisons in its trialsPapers from its trials149
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials6
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Dimensional Change Card Sort | 2 | 0 | ConductCognition |
| Category Fluency | 1 | 1 | ConductCognition |
| 1-Back Task | 1 | 1 | ConductCognition |
| Picture Order Memory Test | 1 | 0 | ConductCognition |
| Size Order Memory Test | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL787
GET https://conductscience.org/api/drugs/v1/CHEMBL787/diseases?page=2